RITUXIMAB (RTX) is an anti-CD20 monoclonal antibody that depletes B cells [1]. It has been reported to be useful for the treatment of autoimmune and hematologic diseases [2, 3], and various other diseases, including type 1 diabetes mellitus (T1DM) [4].

Although Graves’ disease (GD) is an autoimmune disease, to date, no immunosuppressive agents have been adopted for clinical use in patients with GD. The current goal of GD therapy is to normalize and maintain thyroid function by drug therapy with thiamazole (MMI), which suppresses the production of thyroid hormones and/or other molecules, with an aim to restore normal immunoregulatory mechanisms. However, treatment with anti-thyroid drugs is associated with high incidence of serious side effects, such as agranulocytosis (MMI: 0.35%, propylthiouracil (PTU): 0.37% [5]) and liver dysfunction (MMI 30 mg/day: 6.9%, MMI 15 mg/day: 6.6%, PTU 300 mg/day: 26.9% [6]), and the rate of complete remission has been less than satisfactory (approximately 40-50% in Europe [7-10], approximately 40-60% in Japan [11-13], and approximately 50% in USA [14]).

In the context of treatment of thyroid diseases, RTX has been reported to be useful for the treatment of thyroid-associated ophthalmopathy (TAO) [15-17]. In the study of Salvi et al. [15], a significantly greater improvement in Clinical Activity Score, representing an index of proper management of patients with TAO, was observed in patients with TAO complicated by hyperthyroidism after 30 weeks of RTX treatment than after steroid therapy. Relapse of active TAO did not occur in any of the patients treated with RTX, but occurred in 10% of patients who underwent steroid therapy.

Recently, the efficacy of immunosuppressive therapy with RTX for GD has been investigated. RTX therapy leads to the remission of recurrent or active GD and effectively maintains the remission [18-20]. However, to date, there is little or no information on the efficacy and safety of RTX in Japanese patients with
autoimmune polyglandular syndrome (APS), including autoimmune thyroid disease. Herein, we report the successful use of RTX in a patient with GD associated with T1DM, and in whom remission was maintained.

**Clinical Trial Registry**

This trial, RTX treatment for T1DM, was registered with the University Hospital Medical Information Network (UMIN) (No. UMIN000013622).

**Case Report**

In July 2012, a 40-year-old man presented with hyperhidrosis, tremors, and insomnia, but no palpitation. Two months later, the subject experienced thirstiness, polydipsia, polyuria, and a weight loss of 10 kg over the 2-month period. He was diagnosed with thyrotoxicosis [thyroid-stimulating hormone (TSH) <0.05 μIU/mL, free thyroxine (FT4) 4.14 mg/dl] and DM [hemoglobin A1c (HbA1c) 8.5%, plasma glucose over 200 mg/dl], and referred to our hospital for further examination. The thyroid function test results indicated thyrotoxicosis. The thyroid stimulating hormone receptor antibody (TRAb) titer was 12.5 U/mL, and the thyroid ultrasound examination indicated an enlarged thyroid gland and increased blood flow. On the other hand, thyroid stimulating antibody (TSAb) was negative and there were no symptoms of TAO. On the basis of these findings, the patient was diagnosed with GD and diabetes with poor glycemic control (HbA1c level, 9.8%; postprandial plasma glucose level, 227 mg/dL). Urine analysis indicated the presence of ketone bodies, although arterial blood gas analysis indicated no evidence of ketoacidosis (blood pH, 7.378).

The patient was admitted to our department, and treatment for GD with 30 mg of MMI and 50 mg of potassium iodide (KI) was initiated. With regards to the stage of diabetes, the patient was negative for glutamic acid decarboxylase (GAD) antibody (Table 1). In addition, the increased blood glucose levels might have been exacerbated by the oxyhyperglycemia associated with GD. However, owing to the absence of a family history of diabetes and high plasma glucose level at fasting, an islet antigen (IA)-2 antibody test was performed. The patient was positive for IA-2 antibody, with an initial titer of 1.7 U/mL, and was therefore diagnosed with T1DM. After excluding Addison’s dis-

### Table 1  Laboratory data on the first admission

<table>
<thead>
<tr>
<th>CBC</th>
<th>ABG</th>
<th>DM-related</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WBC (×10^3/mm³)</td>
<td>4700</td>
<td>pH 7.38</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>53.9</td>
<td>PCO₂ (Torr) 44.1</td>
</tr>
<tr>
<td>Eosinophils (%)</td>
<td>3.2</td>
<td>HCO₃⁻ (mEq/mL) 25.4</td>
</tr>
<tr>
<td>Basophils (%)</td>
<td>0.2</td>
<td>Total protein (g/dL) 7.3</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>34.4</td>
<td>Albumin (g/dL) 4.4</td>
</tr>
<tr>
<td>Monocytes (%)</td>
<td>8.3</td>
<td>Biochemistry</td>
</tr>
<tr>
<td>RBC (×10^12/mm³)</td>
<td>498</td>
<td>AST (IU/L) 17</td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>13.9</td>
<td>ALT (IU/L) 23</td>
</tr>
<tr>
<td>Hct (%)</td>
<td>39.9</td>
<td>γ-GTP (IU/L) 16</td>
</tr>
<tr>
<td>Platelet count (×10^4/mm³)</td>
<td>18.0</td>
<td>LDL-C (mg/dL) 38</td>
</tr>
<tr>
<td>Platelet count (×10^4/mm³)</td>
<td>18.0</td>
<td>HDL-C (mg/dL) 31</td>
</tr>
<tr>
<td>Urine</td>
<td></td>
<td>TG (mg/dL) 155</td>
</tr>
<tr>
<td>pH</td>
<td>7.38</td>
<td>FT3 (pg/mL) 16.23</td>
</tr>
<tr>
<td>glucose (4+)</td>
<td>BUN (mg/dL) 23</td>
<td>FT4 (ng/dL) &gt;7.77</td>
</tr>
<tr>
<td>protein (-)</td>
<td>Cre (mg/dL) 0.56</td>
<td>TRAb (U/mL) (&lt; 2.0) 12.5</td>
</tr>
<tr>
<td>ketone (1+)</td>
<td>cGFR (mL/min) 126.9</td>
<td>TG-Ab (U/mL) (&lt; 28.0) 47</td>
</tr>
<tr>
<td>O.B. (-)</td>
<td>Na (mEq/mL) 131</td>
<td>TPO-Ab (U/mL) (&lt; 16.0) 50</td>
</tr>
<tr>
<td></td>
<td>K (mEq/mL) 4.4</td>
<td>HLA typing</td>
</tr>
<tr>
<td></td>
<td>Cl (mEq/mL) 95</td>
<td></td>
</tr>
</tbody>
</table>

*normal range*
Thyroid remission in GD by rituximab

Treatment with RTX at a dose of 500 mg (approximately 300 mg/m²) on 2 occasions at a 1-week interval did not cause any side effects, including infusion reactions (e.g., fever, hypotension, and tachycardia) and infection. However, laboratory test results on readmission, including a serum aspartate aminotransferase (AST) level of 83 IU/L, alanine aminotransferase (ALT) level of 114 IU/L, and γ-glutamyl transpeptidase (GTP) level of 210 IU/L, indicated liver dysfunction; hepatitis B surface antigen (HBs-Ag), hepatitis B core antigen (HBc-Ag) and hepatitis C virus antibody (HCV-Ab) were negative. These changes were considered to represent adverse effects of MMI. Accordingly, MMI was discontinued, resulting in the immediate improvement in liver function. Subsequently, the patient was discharged from treatment and was prescribed 50 mg of KI for the hyperthyroidism.

As shown in Fig. 1, the patient’s glycemic levels were stable since hospital discharge. At present, HbA1c level is 6.9 %, and the daily insulin requirement is 6 U, indicating stable glycemic control. C-peptide immunoreactivity (CPI) Index (representing beta cell function) continued to be within the normal range after treatment (baseline: 1.82, after 6-month RTX treatment: 1.50) (Fig. 1). In addition, the IA-2 antibody (initial titer of 1.7 U/mL) was no longer detectable 8 months after RTX administration. As shown in Fig. 2,

---

![Graph](image)

**Fig. 1** Time course of diabetes data
Serial changes in HbA1c level, daily insulin requirement and CPI Index during hospitalization and at follow-up.
Kurozumi et al. serum immunoglobulin (Ig) G level did not change with RTX treatment. RTX was well tolerated with no infusion reaction and no serious infection. Heemstra et al. [18] used RTX for the treatment of 13 patients with relapsing GD, and reported that 9 patients remained in remission at a median follow-up of 18 months, whereas 4 patients were considered non-responders and subsequently treated with radioiodine. These authors found no differences in thyroid size between the 9 responders and the 4 non-responders. However, the baseline FT4 level was significantly higher in the non-responders. Because of the small number of patients, no significant differences were observed in TSH binding inhibitory immunoglobulin (TBII) levels between the responders and non-responders. However, many patients with low TBII levels remained in remission. Moreover, the mean TBII levels decreased significantly in the 9 responders, from a median level of 4 IU/L at baseline to 1.9 IU/L at 26 weeks.

El Fassi and colleagues [19] studied 20 GD patients, among which 10 were treated with RTX (RTX+), whereas 10 were left untreated (RTX−). Furthermore, these patients were treated with MMI for approximately 4 months. Four RTX+ patients remained in remission with a median follow-up of 705 days, whereas all RTX− patients had a relapse within 1 year. The RTX−/RTX+

Discussion

Herein, we described the case of a patient with type 3 APS associated with GD, who was treated with 500 mg of RTX (approximately 300 mg/m²) on 2 occasions 1 week apart. The treatment induced disease remission over a period of 1 year since the diagnosis of GD. The TRAb titers decreased from 11.1 IU/L to undetectable level 4 months after RTX treatment. In addition, serum TRAb level remained undetectable for 1 year, whereas the TRAb level was 11.1 U/mL before RTX treatment, decreased to 6.8 U/mL and 2.1 U/mL at 1 and 3 months after treatment, respectively, and was no longer detectable at 4 months after RTX treatment. Furthermore, thyroid function gradually improved with the reduction of TRAb levels. Because hypothyroidism (TSH 18.65 μIU/mL, FT4 0.68 ng/dL) occurred 4 months after the onset of hyperthyroidism, the KI dosage was reduced to 50 mg every alternate day. TSH and FT4 levels 5 months after onset were 11.91 μIU/mL and 0.78 ng/dL, respectively, and KI was discontinued. At present, approximately 1 year since the diagnosis of GD, the disease remains in remission in the absence of any anti-thyroid drug therapy (TSH, FT4, and TRAb levels: 3.91 μIU/mL, 1.05 ng/dL, and 0.7 U/mL, respectively).

![Time course of thyroid data](image)

**Fig. 2** Time course of thyroid data. Serial changes in thyroid function: FT4, TSH, and TRAb. MMI was discontinued due to liver dysfunction. After readmission, RTX was administered on two occasions one week apart. KI was discontinued following correction of hypothyroidism. Approximately one year after the diagnosis of GD, the disease remains in remission in the absence of any anti-thyroid drug therapy.
Thyroid remission in GD by rituximab

hazard ratio for relapse was 2.30. The mean decrease in TRAb levels was not significantly different between the 2 groups. However, the duration of euthyroidism was inversely correlated with TRAb levels in all patients. Moreover, all patients with baseline TRAb levels of >5 IU/L showed relapse despite the use of RTX, the 5 RTX–patients with baseline TRAb levels of <5 IU/L relapsed, whereas the 4 RTX+ patients with baseline TRAb levels of <5 IU/L remained in remission. The authors concluded that RTX treatment induced sustained remission in patients with low TRAb levels.

Salvi and coworkers [15] used RTX for the treatment of hyperthyroidism in patients with TAO. The mean change in serum TRAb levels after RTX treatment was not significantly different from that of patients treated with intravenous glucocorticoids (IVGC) for 30 weeks. El Fassi et al. [22] reported that RTX therapy, in addition to the standard MMI therapy, prolonged the period of remission with a median follow-up of 400 days. However, it did not induce a reduction in TRAb levels when compared with MMI monotherapy.

RTX exerts its effects primarily through the suppression of B-cell antibody production and depletion of B cells, as reviewed by Hasselbach [20] and Wang et al. [23]. In the patient under study, TRAb titers decreased from 11.1 IU/L before the use of RTX to undetectable levels 4 months after RTX treatment. At the last follow-up examination 1 year after RTX treatment, the serum remained negative for TRAb. However, as described above, the decrease in the TRAb level after RTX treatment was similar to that observed in the control group, when compared with steroid therapy or combination therapy with MMI. Therefore, it appears that other factors, such as the cytokine-producing capacity of B cells and their impact on T cells, may need to be considered. Elevated serum interleukin (IL)-18 levels have been reported in patients with GD [24, 25]. Because RTX was reported to markedly reduce serum IL-18 levels in patients with rheumatoid arthritis [26], the possible involvement of IL-18 cannot be ruled out. Moreover, it has been suggested that in multiple sclerosis [27] and T1DM [4], RTX may suppress T cells through the suppression of the antigen-presenting function of B cells.

In the patient under investigation, T cells were evaluated by lymphocyte analysis, and no apparent changes were observed during the first 6 months after RTX treatment. However, a longer follow-up period is necessary for a more accurate assessment.

El Fassi et al. [19] reported the side effects in 5 of 10 patients after an initial RTX infusion. Four days after the second infusion, 2 patients developed serum sickness (joint pain and fever), and during the 1-year follow-up period, 2 patients had mild infections. In other reports [15, 18], 50% of the patients developed infusion reactions and joint pain after the initial RTX infusion. However, these symptoms were alleviated with acetaminophen and glucocorticoids, and the side effects improved after the second infusion. The patient under study showed no infusion reactions, such as fever, hypotension, tachycardia, and pruritus, after the first or the second dose of RTX. Although serum IgM level decreased from 108 mg/dL (measured before RTX treatment) to 63 mg/dL measured at 9 months after the completion of treatment (Table 2), as reported in previous studies [22], these levels recovered. There were no marked changes in the serum levels of IgG and IgA, and no infections were detected.

Furthermore, Pescovitz et al. [4] reported that RTX treatment was associated with preservation, at least in part, of beta-cell function over a period of 1 year in patients with newly diagnosed type 1 DM. For example, significantly lower levels of HbA1c and lower insulin dose were noted in patients of the RTX group. Similarly, our patient had stable low level of HbA1c, required less insulin after treatment, and RTX treatment effectively preserved beta-cell function (e.g., CPR Index continued to be within the normal range after treatment).

Herein, we described the case of a patient with type 3 APS associated with GD, in whom remission was maintained for 1 year after treatment with RTX. With regard to the treatment of GD patients, it has been

---

**Table 2** Serial changes in immunoglobulin before administration of RTX and follow-up

<table>
<thead>
<tr>
<th></th>
<th>Before administration of RTX</th>
<th>After 9 months</th>
<th>After 1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG (mg/dL)</td>
<td>(778-1604)</td>
<td>1286</td>
<td>1203</td>
</tr>
<tr>
<td>IgA (mg/dL)</td>
<td>(117-413)</td>
<td>213</td>
<td>253</td>
</tr>
<tr>
<td>IgM (mg/dL)</td>
<td>(37-200)</td>
<td>108</td>
<td>63</td>
</tr>
</tbody>
</table>

normal range
reported that RTX is effective in patients with relatively low serum titers of TRAb. In particular, RTX may exhibit good efficacy in properly selected candidates, including those who cannot be treated with anti-thyroid drugs because of their adverse effects, those who do not desire either surgery or isotope therapy, those who cannot be treated with isotopes because of the TAO, and those for whom RTX is expected to be effective for the ophthalmopathy itself. In contrast to surgery or isotope therapy, RTX administration does not require replacement therapy after treatment. Although some issues need to be resolved, such as the assessment of safety and cost, the effectiveness of RTX for the treatment of GD can be demonstrated in the near future through randomized controlled trials. In the meantime, we will perform a thorough patient follow-up to assess thyroid function, potential adverse events, and overall health status.

References


1769-1772.


